|

Breast Cancer Clinical Trials in New Hampshire

28 recruiting studies across 9 cities

All Trials in New Hampshire

Phase
Trial Phase Location
ATEMPT 2.0: Adjuvant T-DM1 vs THPhase 2Concord
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—Concord
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3Concord
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Concord
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Concord
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/AConcord
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Concord
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3Concord
Testing a Mammography Decision Intervention in a Rural SettingN/AKeene
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3Laconia
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsPhase 1Lebanon
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1Lebanon
A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulationN/ALebanon
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3Lebanon
A Study of Tetrathiomolybdate (TM) Plus CapecitabinePhase 1/2Lebanon
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3Lebanon
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.Phase 4Lebanon
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)Phase 1Lebanon
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer PatientsPhase 2Lebanon
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorPhase 2Lebanon
MRg-NIRS Imaging System Breast Cancer TrialN/ALebanon
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPhase 3Lebanon
Pilot SMART of a Remotely Delivered, Physical Activity Intervention for Breast Cancer SurvivorsN/ALebanon
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)Phase 2Lebanon
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast CancerPhase 1Lebanon
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Phase 3Lebanon
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerPhase 2Lebanon
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyPhase 3Londonderry

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.